CV Sciences, Inc. reported its financial results for the second quarter of 2025, revealing a decrease in sales to $3.6 million compared to $4.0 million in the same period of 2024. This represents an 8% decline, primarily attributed to lower sales volume, influenced by state regulatory pressures. The gross margin improved to 50.9% from 47.0% in the second quarter of 2024, marking the highest gross margin since the third quarter of 2019. The company reported an operating loss of $0.1 million, a significant improvement from the $0.6 million operating loss in the same quarter of the previous year, mainly due to reduced selling, general, and administrative expenses. CV Sciences achieved a positive adjusted EBITDA of $0.1 million, contrasting with a negative adjusted EBITDA of $6,000 in the prior year's second quarter. 39% of the net revenue for this quarter came from new products launched since January 1, 2023, with a total of 34 new products introduced during this period. The company anticipates further improvements in gross margin in the latter half of 2025, supported by in-sourcing production through its acquisition of Elevated Softgels and ongoing product innovation.